Comparative Pharmacology
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus PRADAXA.
FONDAPARINUX SODIUM vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%)
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category C
Category C
Anticoagulant
Anticoagulant